Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration

Neurology

Volumn 58, Issue 11, 2002, Pages 1622-1628

  Riemenschneider, M ^a   Wagenpfeil, S ^b   Diehl, J ^a   Lautenschlager, N ^a   Theml, T ^a   Heldmann, B ^a   Drzezga, A ^a   Jahn, T ^a   Forstl H ^a   Kurz, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; BRAIN DEGENERATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ALZHEIMER DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PATHOLOGY; SENILE PLAQUE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SENILE PLAQUES; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 0037062351     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.58.11.1622     Document Type: Article

References (41)

1. Pathological tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration
2. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay
3. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
4. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer's disease
5. Tau in cerebro-spinal fluid: An antemortem marker for Alzheimer's disease?
6. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type
7. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
8. Improved discrimination of Alzheimer's disease patients using beta-amyloid (1-42) and tau levels in CSF
9. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow up study
10. Cerebrospinal protein tau is elevated in early Alzheimer's disease
11. Elevated levels of Tau protein in CSF of patients with Creutzfeldt-Jakob disease
12. Increased CSF tau protein in corticobasal degeneration
13. Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer's disease
14. High cerebrospinal fluid tau and low amyloid beta 42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype
15. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease
16. Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: Association with apolipoprotein E genotype and cognitive decline
17. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease
18. Tau protein in cerebrospinal fluid from semantic dementia patients
19. 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
20. Mental and behavioural disorders (F00-F99)
21. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
22. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
23. A standardized instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia
24. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery
25. "Mini Mental State." A practical method for grading the cognitive state of patients for the clinician
26. The Clinical Dementia Rating (CDR): Current version and scoring rules
27. Development of a specific diagnostic test for measurement of β-amyloid (1-42) in CSF
28. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes
29. Comparing the area under two or more correlated receiver operating characteristic curves: A nonparametric approach
30. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
31. Beta-trace protein in cerebrospinal fluid: A blood-CSF barrier-related evaluation in neurological diseases
32. CSF flow-its influence on CSF concentration of brain-derived and blood-derived proteins
33. Blood-brain-cerebrospinal fluid barriers
34. 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
35. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease
36. Intraneuronal Aβ42 accumulation in human brain
37. Consensus report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease
38. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
39. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada
40. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values